All In Biotech

Drug Trial Radar · NCT07024693

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

A Phase 2, Multicenter, Open-Label Study to Assess the Pharmacodynamics, Safety, and Tolerability of DT-168 Ophthalmic Solution in Patients With Fuchs Endothelial Corneal Dystrophy Undergoing Keratoplasty

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Jul 30, 2025

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Design Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.

Conditions

  • Fuchs Endothelial Corneal Dystrophy
  • Fuchs

Interventions

  • DT-168Drug

    Active

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. FECD Biomarkers: Splicing PanelTime frame: Perioperative

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • DTX-168-201 Study Site

    Indianapolis, Indiana · Recruiting

  • DTX-168-201 Study Site

    Grand Rapids, Michigan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.